FOLFIRI: Clinical Trials

61 trials of FOLFIRI, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 8 terminated, 8 unknown, 5 recruiting. 61 Phase 2, 12 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 261Completed 32, Terminated 8, Unknown 8, Recruiting 5, Active not recruiting 4, Not yet recruiting 2, Suspended 1, Withdrawn 1
Phase 112Completed 5, Terminated 5, Recruiting 1, Suspended 1
Phase 35Completed 2, Unknown 2, Recruiting 1

Follow FOLFIRI: new trials by email Literature Review of FOLFIRI trials Research Report on FOLFIRI

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer
Phase 2Not yet recruitingJun Huang1142026-06-012026-04-28
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC
Phase 2RecruitingOncolytics Biotech602026-04-302026-11-05
A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
Inavolisib, Bevacizumab, FOLFOX - Colorectal Cancer
Phase 2WithdrawnHoffmann-La Roche2026-02-012026-02-09
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 2 / Phase 3RecruitingBristol-Myers Squibb9902025-12-312026-10-23
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
AK112, FOLFIRI, Bevacizumab - Colorectal Cancer, Ivonescimab
Phase 2Not yet recruitingSun Yat-sen University1302025-08-102025-06-15
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
Niraparib, FOLFIRI, Ipilimumab - Pancreatic Adenocarcinoma Metastatic
Phase 2RecruitingAbramson Cancer Center at Penn Medicine682025-05-072026-10-13
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms
Phase 2RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS252024-06-032025-02-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Onvansertib, FOLFIRI, Bevacizumab - Metastatic Colorectal Cancer, CRC
Phase 2Active not recruitingCardiff Oncology1102024-02-272026-11-10
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
PM8002, FOLFIRI - Neuroendocrine Neoplasm
Phase 2Active not recruitingBiotheus Inc.312023-05-172026-07-09
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1 / Phase 2RecruitingInstitut de Recherches Internationales Servier5542023-04-182026-10-13
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Onvansertib, FOLFIRI, Bevacizumab - Colorectal Cancer, Metastatic Colorectal Cancer
Phase 2CompletedCardiff Oncology232023-03-172025-01-10
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Ametumumab, Anti-PD-1 monoclonal antibody, Cetuximab - Colorectal Cancer
Phase 2UnknownShanghai Celfuture Biotech Co., Ltd.842023-01-012023-02-01
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fruquintinib, FOLFIRI, mFOLFOX6 - Metastatic Colorectal Cancer
Phase 2UnknownFudan University682022-12-012022-12-02
Switch Maintenance in Pancreatic
ZIMBERELIMAB, DOMVANALIMAB, APX005M - Pancreatic Cancer, Adenocarcinoma of the Pancreas
Phase 1 / Phase 2SuspendedJames Cleary, MD, PhD462022-11-302026-06-04
Phase 2 Study of DKN-01 in Colorectal Cancer
DKN-01, FOLFIRI, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma
Phase 2CompletedLeap Therapeutics, Inc.1882022-08-302025-08-03
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer
Phase 2TerminatedNovartis Pharmaceuticals2042021-11-152025-03-26
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer
Phase 2 / Phase 3UnknownRuijin Hospital2002021-11-012021-04-30
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib, Cetuximab, FOLFIRI - BRAF V600E, Metastatic Colorectal Cancer
Phase 2CompletedPierre Fabre Medicament1072021-09-142026-04-30
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
Cetuximab, FOLFIRI, FOLFOX regimen - Metastatic Colorectal Adenocarcinoma
Phase 2Active not recruitingUniversity of Campania Luigi Vanvitelli2192021-07-152025-05-25
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
FOLFIRI, OSE2101 - Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer
Phase 2Active not recruitingGERCOR - Multidisciplinary Oncology Cooperative Group1062021-04-102025-07-25

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (45)  ·  Colonic Neoplasms (11)  ·  Rectal Neoplasms (9)  ·  Neoplasm Metastasis (7)  ·  Neoplasms (5)  ·  Pancreatic Neoplasms (3)  ·  Adenocarcinoma (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Exanthema (1)  ·  Gastrointestinal Neoplasms (1)  ·  Histiocytosis (1)

Sponsors

Amgen (4)  ·  Cardiff Oncology (3)  ·  Fudan University (3)  ·  Eisai Inc. (2)  ·  Genentech, Inc. (2)  ·  Hoffmann-La Roche (2)  ·  Ruijin Hospital (2)  ·  4SC AG (1)  ·  AbbVie (1)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Biotheus Inc. (1)  ·  Bristol-Myers Squibb (1)  ·  CR-CSSS Champlain-Charles-Le Moyne (1)  ·  Central European Cooperative Oncology Group (1)  ·  Centre Hospitalier Universitaire de Besancon (1)

Countries

United States (21)  ·  Italy (12)  ·  Spain (11)  ·  China (10)  ·  France (9)  ·  Germany (7)  ·  Australia (6)  ·  South Korea (5)  ·  United Kingdom (5)  ·  Belgium (4)  ·  Canada (4)  ·  Singapore (4)  ·  Argentina (3)  ·  Austria (3)  ·  Czechia (3)

Top investigators

Harish Dave (2)  ·  Roberto Labianca, MD (2)  ·  Alberto Zaniboni, MD (1)  ·  Armando Santoro, MD (1)  ·  Benoit Samson, MD (1)  ·  Changping Wu, M.D. (1)  ·  Cynthia Sirard (1)

Results publications

PMID 22070868, PMID 39475591, PMID 22000810, PMID 22576338, PMID 23361051, PMID 23493136, PMID 23955585, PMID 24905030, PMID 30080723, PMID 30840064, PMID 31300973, PMID 31515083, PMID 32766143, PMID 34646387, PMID 35202974, PMID 35484400, PMID 36739879, PMID 36860319, PMID 37337155, PMID 38231047, PMID 41852303, PMID 42736431

NIH funding

2025 (3), 2008 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1), 2023 (1)